|
Market Closed -
Toronto S.E.
15:59:40 2026-10-02 EDT
|
5-day change | 1st Jan Change | ||
| 20.65 CAD | +1.52% |
|
-2.87% | +6.88% |
| 10-02 | Grail's cancer blood test nears landmark FDA approval, but insurance coverage looms | RE |
| 10-01 | Cardinal Health renews contract with CVS Health |  |
| Market Cap | 111B 98.25B 91.7B 83.58B 158B 10,630B 159B 1,110B 430B 5,434B 415B 406B 17,441B | P/E 2026 * |
12.6x | P/E 2027 * | 12x |
|---|---|---|---|---|---|
| Enterprise Value | 162B 144B 135B 123B 232B 15,619B 234B 1,630B 632B 7,984B 610B 597B 25,625B | EV / Sales 2026 * |
0.39x | EV / Sales 2027 * | 0.37x |
| Free-Float |
71.17% | Yield 2026 * |
3.08% | Yield 2027 * | 3.17% |
| Markets | Quality | ||
|---|---|---|---|
Toronto S.E.
| CVS | Delayed | |
Deutsche Boerse AG
| CVS0 | Delayed |
Last Transcript: CVS Health Corporation
| 1 day | +1.52% | ||
| 1 week | -2.87% | ||
| Current month | +0.88% | ||
| 1 month | -11.11% | ||
| 3 months | -19.27% | ||
| 6 months | +16.34% | ||
| Current year | +6.88% |
| 1 week | 20.13 |  | 21.51 |
| 1 month | 20.13 | | 23.12 |
| Current year | 16.84 | | 26.46 |
| 1 year | 16.84 | | 26.46 |
| 3 years | 10.85 | | 26.46 |
| 5 years | 10.85 | | 26.61 |
| 10 years | 10.85 | | 26.61 |
| Manager | Title | Age | Since |
|---|---|---|---|
J. Joyner
CEO | Chief Executive Officer | 62 | 2024-10-16 |
Ali Keshavarz
PSD | President | - | - |
Brian Newman
DFI | Director of Finance/CFO | 57 | 2025-05-11 |
| Director | Title | Age | Since |
|---|---|---|---|
C. Brown
BRD | Director/Board Member | 74 | 2007-02-28 |
Anne Finucane
BRD | Director/Board Member | 73 | 2011-01-19 |
| Director/Board Member | 71 | 2015-03-04 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.52% | -2.87% | - | - | 111B | |
| +1.48% | -3.00% | +11.58% | +24.85% | 111B | |
| +0.78% | -2.05% | -0.66% | +74.89% | 92.38B | |
| +0.46% | -0.54% | +145.20% | +833.67% | 59.15B | |
| -0.38% | -5.45% | -7.47% | +54.41% | 27.66B | |
| +0.97% | -1.27% | +30.11% | +92.79% | 25.75B | |
| +1.28% | -0.37% | +11.39% | +53.88% | 25.02B | |
| -0.57% | +0.09% | -15.78% | -6.63% | 20.99B | |
| +1.83% | -0.42% | +27.40% | +309.14% | 20.82B | |
| +1.30% | -2.86% | -4.06% | +34.25% | 16.87B | |
| Average | +0.87% | -1.83% | +21.97% | +163.47% | 44.36B | |
| Weighted average by Cap. | +1.03% | -2.05% | +27.13% | +178.08% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 418B 371B 347B 316B 596B 40,188B 601B 4,195B 1,626B 20,545B 1,570B 1,535B 65,936B | 430B 382B 357B 325B 613B 41,334B 619B 4,315B 1,672B 21,131B 1,614B 1,579B 67,816B |
| Net income | 8.87B 7.89B 7.36B 6.71B 12.65B 853B 12.77B 89.07B 34.51B 436B 33.32B 32.6B 1,400B | 9.32B 8.28B 7.73B 7.04B 13.28B 896B 13.41B 93.52B 36.24B 458B 34.99B 34.23B 1,470B |
| Net Debt | 51.89B 46.1B 43.03B 39.22B 73.97B 4,988B 74.66B 521B 202B 2,550B 195B 191B 8,184B | 48.85B 43.4B 40.51B 36.92B 69.63B 4,696B 70.28B 490B 190B 2,400B 183B 179B 7,704B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-02 | $20.65 | +1.52% | 11,404 |
| 26-10-01 | $20.34 | -0.64% | 7,909 |
| 26-09-30 | $20.47 | -1.44% | 10,002 |
| 26-09-29 | $20.77 | -1.05% | 2,998 |
| 26-09-28 | $20.99 | -1.27% | 3,060 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CVS Stock
- CVS Stock
Select your edition
All financial news and data tailored to specific country editions
